AUGIS welcomes NICE approval of durvalumab + perioperative FLOT for selected patients with resectable gastric and GOJ adenocarcinoma.
This marks an important step forward in integrating immunotherapy into curative upper GI pathways, following the MATTERHORN study.
Careful multidisciplinary implementation, ongoing clinical trial participation, and prospective real-world evaluation will be essential as this approach is introduced across the UK.
AUGIS will support national collaboration to better understand outcomes, toxicity and optimal patient selection.
👉 Read the full AUGIS statement below